Cell line · CVCL_0069
Papers89
1 to 20 of 89
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Cytotoxic Dihydroagarofuran Sesquiterpenoids Isolated From the Roots of Tripterygium wilfordii. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HRAS promotes mutant NRAS-driven transformation with codon and allele specificity. | Sci Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Global analysis of cancer cell responses to USP9X inhibition. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tissue-dependent mechanosensing by cells derived from human tumors. | NPJ Biol Phys Mech | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The integrated stress response drives MET oncogene overexpression in cancers. | EMBO J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. | NAR Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Elevated Serum Gastrin Is Associated with Melanoma Progression: Putative Role in Increased Migration and Invasion of Melanoma Cells. | Int J Mol Sci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Piezo1 Activation Prevents Spheroid Formation by Malignant Melanoma SK-MEL-2 Cells. | Int J Mol Sci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| An adverse tumor-protective effect of IDO1 inhibition. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species. | Sci Adv | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0069/papers